Editor’s Comment: Alpha -1 Antitrypsin protects tissues from enzymes of inflammatory cells. The FDA has approved the use of three alpha 1-antitrypsin products derived from human plasma: Prolastin, Zemaira, and Aralast. Alpha -1 Antitrypsin treatment is extremely expensive.
By J. Alegre et al.
Several lines of evidence support the involvement of inflammatory and immunologic abnormalities in chronic fatigue syndrome (CFS). Since recent studies have shown that alpha-1 antitrypsin (AAT) possesses anti-inflammatory properties, the potential therapeutic effect of AAT treatment on CFS has been investigated.
A 49-year-old woman diagnosed with CFS was treated with intravenous infusions of a human plasma-derived AAT concentrate (60 mg/kg body weight weekly for 8 consecutive weeks). The patient's monocyte elastase, a regulator of inflammatory processes, was 1170 U/mg.
At completion of treatment, improvement in maximal workload was observed (54.0-71.7% of predicted). Additionally, amelioration in working memory (scores: 83-94) and perceptual organization (scores: 75-83) were detected on the Wechsler Adult Intelligence Scale-III test. Monocyte elastase decreased to a normal range (<150 U/mg).
Improvement in functional capacity allowed the patient to work in part-time employment.
: These findings suggest a possible role for AAT in the treatment of CFS.
: Alegre J, Camprubí S, García-Quintana A. Pain Manag
. 2013 Mar;3(2):119-22. doi: 10.2217/pmt.12.84.